PMID- 23769095
OWN - NLM
STAT- MEDLINE
DCOM- 20140127
LR  - 20130617
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 45
IP  - 5
DP  - 2013 Jun
TI  - Comparative performance evaluation of a donor-specific bead-based crossmatch 
      technique for the detection of donor-specific anti-HLA antibodies in heart 
      transplantation.
PG  - 2005-8
LID - S0041-1345(13)00187-5 [pii]
LID - 10.1016/j.transproceed.2013.02.038 [doi]
AB  - INTRODUCTION: Recently new human leukocyte antigen (HLA) antibody screening 
      methods have been shown to significantly improve thoracic transplantation 
      outcomes. The best combination of assays for both allocation and monitoring is 
      still under investigation. Herein, we evaluated the correlation and clinical 
      relevance of three methodologies to detect donor-specific anti-HLA antibodies 
      (DSA). METHODS: For the same donor-recipient combinations we compared the results 
      of the Luminex donor-specific crossmatch (DSA-LX), using donor-isolated HLA 
      antigens coated onto microbeads, with those of a flow-cytometric crossmatch 
      (FCXM) and of the Luminex single-antigen bead methodology (SA-LX), wherein 
      recombinant HLA molecules are coated onto microbeads. We compared 46 pre- (n = 
      27) and post-transplant (n = 19) serum samples using DSA-LX and SA-LX, while 27 
      pretransplant samples were additionally analyzed by FCXM. RESULTS: Among the 
      pretransplant sera, the 3 methods were in agreement for class I DSA in 22/27 
      (81.5%) samples and for class II DSA in 17/27 (63.0%) of tested samples. When the 
      results of the 2 bead-based methodologies were compared with the FCXM 
      methodology, the SA-LX results better correlated than the DSA-LX results both for 
      class I and class II antibodies. Furthermore, the SA-LX results showed greater 
      clinical relevance. The reproducibility scores for both the SA-LX and FCXM were 
      100%, whereas for the DSA-LX it was 85.5%. CONCLUSIONS: DSA-LX did not correlate 
      with FCXM and SA-LX to detect DSA, particularly for class II antibodies. 
      Furthermore, in comparison to FCXM and SA-LX, DSA-LX showed lower reproducibility 
      rendering the method not eligible for prediction, allocation, or monitoring 
      purposes.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Chaidaroglou, A
AU  - Chaidaroglou A
AD  - Molecular Immunopathology and Histocompatibility Laboratory, Onassis Cardiac 
      Surgery Center, Athens, Greece. chaidaroglou@ocsc.gr
FAU - Skoura, A
AU  - Skoura A
FAU - Degiannis, D
AU  - Degiannis D
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Autoantibodies)
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Autoantibodies/*blood
MH  - Flow Cytometry
MH  - HLA Antigens/*immunology
MH  - *Heart Transplantation
MH  - Histocompatibility Testing
MH  - Humans
MH  - Reproducibility of Results
MH  - Retrospective Studies
MH  - *Tissue Donors
EDAT- 2013/06/19 06:00
MHDA- 2014/01/28 06:00
CRDT- 2013/06/18 06:00
PHST- 2012/12/14 00:00 [received]
PHST- 2013/01/21 00:00 [revised]
PHST- 2013/02/01 00:00 [accepted]
PHST- 2013/06/18 06:00 [entrez]
PHST- 2013/06/19 06:00 [pubmed]
PHST- 2014/01/28 06:00 [medline]
AID - S0041-1345(13)00187-5 [pii]
AID - 10.1016/j.transproceed.2013.02.038 [doi]
PST - ppublish
SO  - Transplant Proc. 2013 Jun;45(5):2005-8. doi: 10.1016/j.transproceed.2013.02.038.